A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care.
View the Press ReleaseSWOG Cancer Research Network is part of the National Cancer Institute’s National Clinical Trials Network and the NCI Community Oncology Research Program. SWOG has more than 20,000 members in 46 states and seven other countries who design and conduct clinical trials and translational research to improve the lives of people with cancer. SWOG trials have led to the approval of 15 cancer drug regimens, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org